Indaptus Therapeutics Inc

Change company Symbol lookup

Select an option...

INDP Indaptus Therapeutics Inc

FUSN Fusion Pharmaceuticals Inc

RDUS Schnitzer Steel Industries Inc

ALEC Alector Inc

LZM Lifezone Metals Ltd

LMRMF Lomiko Metals Inc

SOXL Direxion Daily Semiconductor Bull 3X Shares

OXSQ Oxford Square Capital Corp

BAER Bridger Aerospace Group Holdings Inc

CMRA Comera Life Sciences Holdings Inc

Go

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.